TeamDrive
RUS
Victor Stankevich

Victor Stankevich

Founding Partner, CEO

Телефоны:

+7 495 545-39-12

Send message

Viktor Stankevich is a Founding Partner of RMI Partners, a venture capital investment company in the area of innovative biopharmaceutical products.

Viktor has extensive experience of establishing and developing major projects in different sectors of the economy. In 2006-2012 Victor held different management positions at Mobile TeleSystems (MTS), one of Russia’s largest telecommunications companies. At MTS Group he was Director of External Resource Management and Control, and in 2010 was appointed Head of Procurement and a member of the Management Board.

Previously Victor spent more than 10 years (1996-2006) developing ROSNO insurance company. After becoming a leading player on the Russian insurance market, ROSNO was acquired by the world’s largest insurance company Allianz Holding. Victor was promoted from Head of Treasury to Deputy CEO. His “portfolio” of professional experience includes participation in the foundation of the Institute of Design Automation of the USSR Academy of Sciences, where he was in charge of the laboratory of artificial intelligence systems in design automation.

Victor graduated from Moscow Aviation Institute as a radio engineer, and from the Russian Foreign Trade Academy, specialising in international economic relations. Victor acquired an additional degree in 2002 from the Financial University under the Government of the Russian Federation, specialising in economics and finance.

Media Center

  • 22 September 2017

    SPIC’s will ensure more predictability for pharmaceutical companies in Russia

    A meeting of the working group of the Coordination Council in the Area of Circulation of Medicines and Medical Devices held in the Russian Union of Industrialists and Entrepreneurs (RSPP) examined the state and development prospects of manufacturing the drugs for the treatment of oncological diseases in Russia.

  • 22 September 2017

    Cancer biobank Indivumed and CRO Helomics team up on precision medicine

    Indivumed, which has a large cancer biobank, has partnered with cancer research specialist Helomics to analyze human cancer biospecimens and relevant clinical datIndivumed, which has a large cancer biobank, has partnered with cancer research specialist Helomics to analyze human cancer biospecimens and relevant clinical data collected from patients around the world to help advance research in personalized cancer treatments. collected from patients around the world to help advance research in personalized cancer treatments.

  • 21 September 2017

    In a world of change, big pharma remains a constant

    Analysts casting their eyes forward to 2022 see big pharma maintaining its position in the sector, protected by vast war chests and ready to pounce on any newcomer that shows promise. Here pharmaphorum’s Andrew McConaghie crunches the numbers.

  • 20 September 2017

    India’s Zydus Cadila inks deal to produce varicella vaccine in Russia

    India’s Zydus Cadila inks deal to produce varicella vaccine in Russia

    Zydus Cadila, an Indian injectables maker, said it reached a deal with Russia’s Pharm Aid to manufacture its varicella vaccine for the Russian Federation. The Russians have been pressuring foreign pharmaceutical companies to engage in local production if they want to be in its market. Earlier this year, Russia-based NovaMedica announced it began work on a new plant in Russia’s Kaluga region where it will produce 30 of Pfizer’s sterile injected generic medications for the local market.

Read more